MX367404B - Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides. - Google Patents

Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides.

Info

Publication number
MX367404B
MX367404B MX2017000183A MX2017000183A MX367404B MX 367404 B MX367404 B MX 367404B MX 2017000183 A MX2017000183 A MX 2017000183A MX 2017000183 A MX2017000183 A MX 2017000183A MX 367404 B MX367404 B MX 367404B
Authority
MX
Mexico
Prior art keywords
mineralocorticoid receptor
receptor modulators
benzoxazinone
amides
benzoxazinone amides
Prior art date
Application number
MX2017000183A
Other languages
English (en)
Other versions
MX2017000183A (es
Inventor
O´MAHONY Gavin
Kossenjans Michael
Edman Karl
Kajanus Johan
Anders Hogner Carl
Cornwall Philip
Turner Andrew
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2017000183A publication Critical patent/MX2017000183A/es
Publication of MX367404B publication Critical patent/MX367404B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Se describen ciertos derivados de amidas de benzoxazinona de fórmula (I) o sus sales farmacéuticamente aceptables, que actúan como moduladores del receptor de mineralocorticoides (MR) que pueden reducir el estrés oxidativo en el endotelio y, por lo tanto, mejorar la función vascular, métodos para su potencial uso terapéutico, composiciones farmacéuticas que los contienen y procesos para preparar tales compuestos.
MX2017000183A 2014-06-30 2015-06-26 Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides. MX367404B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462018790P 2014-06-30 2014-06-30
PCT/GB2015/051860 WO2016001631A1 (en) 2014-06-30 2015-06-26 Benzoxazinone amides as mineralocorticoid receptor modulators

Publications (2)

Publication Number Publication Date
MX2017000183A MX2017000183A (es) 2017-04-25
MX367404B true MX367404B (es) 2019-08-20

Family

ID=53539739

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017000183A MX367404B (es) 2014-06-30 2015-06-26 Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides.

Country Status (26)

Country Link
US (2) US10017502B2 (es)
EP (1) EP3160948B1 (es)
JP (1) JP6368383B2 (es)
KR (1) KR102012222B1 (es)
CN (1) CN106536491B (es)
AR (1) AR101036A1 (es)
AU (1) AU2015282450C1 (es)
CA (1) CA2953655C (es)
CY (1) CY1121596T1 (es)
DK (1) DK3160948T3 (es)
EA (1) EA029518B1 (es)
ES (1) ES2707726T3 (es)
HR (1) HRP20190147T1 (es)
HU (1) HUE042370T2 (es)
LT (1) LT3160948T (es)
ME (1) ME03316B (es)
MX (1) MX367404B (es)
PL (1) PL3160948T3 (es)
PT (1) PT3160948T (es)
RS (1) RS58274B1 (es)
SI (1) SI3160948T1 (es)
SM (1) SMT201900039T1 (es)
TR (1) TR201900659T4 (es)
TW (1) TWI677498B (es)
UY (1) UY36195A (es)
WO (1) WO2016001631A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201900659T4 (tr) * 2014-06-30 2019-02-21 Astrazeneca Ab Mineralokortikoid reseptör modülatörleri olarak benzoksazinon amidleri.
MY210508A (en) 2018-07-19 2025-09-28 Astrazeneca Ab Methods of treating hfpef employing dapagliflozin and compositions comprising the same
CN112107568B (zh) * 2019-06-19 2022-03-25 北京龙嘉博创医药科技有限公司 二芳基酰胺类化合物及其应用
PE20211267A1 (es) * 2019-08-30 2021-07-19 Astrazeneca Ab Metodos de tratamiento de la insuficiencia cardiaca con fraccion de eyeccion reducida con dapagliflozina
EP4188389B1 (en) 2020-07-27 2025-09-17 AstraZeneca AB Dapagliflozin for use in methods of treating chronic kidney disease
US12409186B2 (en) 2020-07-27 2025-09-09 Astrazeneca Ab Methods of treating chronic kidney disease with dapagliflozin
EP4357336A4 (en) * 2021-06-15 2025-07-02 Chia Tai Tianqing Pharmaceutical Group Co Ltd BENZOXAZINONE DERIVATIVES
TW202409023A (zh) 2022-07-14 2024-03-01 美商富曼西公司 除草苯并𠯤
JP2025527854A (ja) 2022-09-01 2025-08-22 アストラゼネカ・アクチエボラーグ 心腎疾患の治療に使用するためのｓｇｌｔ２阻害剤と鉱質コルチコイド受容体調節剤との組み合わせ
CN120344508A (zh) * 2022-12-15 2025-07-18 正大天晴药业集团股份有限公司 苯并恶嗪酮类化合物的结晶及其制备
WO2025111184A1 (en) 2023-11-21 2025-05-30 Fmc Corporation Substituted tetrahydroquinoline and tetrahydroquinoxaline herbicides

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6951855B2 (en) * 2001-04-23 2005-10-04 Astrazeneca Ab Benzoxazinone derivatives for use in the treatment of angiogenesis
BR0317572A (pt) * 2002-12-20 2005-11-22 Warner Lambert Co Benzoxazinas e seus derivados como inibidores de pi3ks
WO2006019716A1 (en) * 2004-07-14 2006-02-23 Ligand Pharmaceuticals, Inc. Intracellular receptor modulator compounds and methods
BRPI0512674A (pt) * 2004-07-28 2007-09-25 Irm Llc compostos e composições como moduladores de receptores nucleares de hormÈnio esteróide
WO2007077961A2 (en) 2005-12-28 2007-07-12 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds and their use as mineralocorticoid receptor ligands
TWI385161B (zh) 2006-02-02 2013-02-11 Mitsubishi Tanabe Pharma Corp 含氮雜雙環化合物
BRPI0717937A2 (pt) 2006-10-31 2013-12-03 Pfizer Prod Inc Compostos de pirazona como antagonistas do receptor mineralocorticóide
DE102007009494A1 (de) 2007-02-27 2008-08-28 Bayer Healthcare Ag Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung
WO2008118319A2 (en) 2007-03-23 2008-10-02 Merck & Co., Inc. Mineralocorticoid receptor modulators
DK2133330T3 (da) 2007-04-09 2014-03-31 Daiichi Sankyo Co Ltd Atropisomer af pyrrolderivat
US8258131B2 (en) 2007-08-01 2012-09-04 Mitsubishi Tanabe Pharma Corporation Fused bicyclic compound
JP5173653B2 (ja) * 2007-08-01 2013-04-03 田辺三菱製薬株式会社 医薬組成物
PE20091057A1 (es) 2007-12-19 2009-07-20 Lilly Co Eli Antagonistas del receptor mineralcorticoide y metodos de uso
KR20110017456A (ko) * 2008-06-18 2011-02-21 아스트라제네카 아베 호흡기 장애의 치료를 위한 베타2-아드레날린성 수용체 효능제로서 작용하는 벤족사지논 유도체
US20100094000A1 (en) 2008-09-03 2010-04-15 Takeda Pharmaceutical Company Limited Pyrazole compounds
WO2010098286A1 (ja) 2009-02-25 2010-09-02 第一三共株式会社 ミネラルコルチコイド受容体拮抗薬を含有する医薬
MX2011009506A (es) 2009-03-12 2011-09-28 Lilly Co Eli Antagonista del receptor mineralcorticoide y metodos de uso.
US20120022058A1 (en) 2009-04-10 2012-01-26 Pfizer Inc. 4,5-dihydro-1h-pyrazole compounds and their pharmaceutical uses
CN102906495B (zh) 2010-05-11 2016-08-24 皇家飞利浦电子股份有限公司 照明模块
CA2798831A1 (en) 2010-05-11 2011-11-17 Pfizer Inc. Morpholine compounds as mineralocorticoid receptor antagonists
TW201216957A (en) 2010-07-13 2012-05-01 Dainippon Sumitomo Pharma Co Biarylamide derivative or a pharmaceutically acceptable salt thereof
WO2012064631A1 (en) 2010-11-10 2012-05-18 Boehringer Ingelheim International Gmbh Pyridyl ureas as mineralocorticoid receptor antagonists
TR201900659T4 (tr) * 2014-06-30 2019-02-21 Astrazeneca Ab Mineralokortikoid reseptör modülatörleri olarak benzoksazinon amidleri.

Also Published As

Publication number Publication date
EA201790046A1 (ru) 2017-08-31
US20170217945A1 (en) 2017-08-03
CY1121596T1 (el) 2020-05-29
TWI677498B (zh) 2019-11-21
EP3160948B1 (en) 2018-10-24
CN106536491A (zh) 2017-03-22
KR20170021883A (ko) 2017-02-28
CN106536491B (zh) 2018-12-18
TR201900659T4 (tr) 2019-02-21
DK3160948T3 (en) 2019-02-18
SI3160948T1 (sl) 2020-06-30
HRP20190147T1 (hr) 2019-03-22
US20150376170A1 (en) 2015-12-31
JP2017522300A (ja) 2017-08-10
EA029518B1 (ru) 2018-04-30
ME03316B (me) 2019-10-20
AU2015282450C1 (en) 2018-09-20
PT3160948T (pt) 2019-02-01
EP3160948A1 (en) 2017-05-03
AU2015282450B2 (en) 2018-05-10
AU2015282450A1 (en) 2017-02-02
CA2953655A1 (en) 2016-01-07
TW201613909A (en) 2016-04-16
AR101036A1 (es) 2016-11-16
ES2707726T3 (es) 2019-04-04
LT3160948T (lt) 2019-02-11
RS58274B1 (sr) 2019-03-29
PL3160948T3 (pl) 2019-04-30
MX2017000183A (es) 2017-04-25
KR102012222B1 (ko) 2019-10-21
US9394291B2 (en) 2016-07-19
UY36195A (es) 2016-01-08
US10017502B2 (en) 2018-07-10
JP6368383B2 (ja) 2018-08-01
WO2016001631A1 (en) 2016-01-07
SMT201900039T1 (it) 2019-02-28
CA2953655C (en) 2020-05-12
HUE042370T2 (hu) 2019-06-28

Similar Documents

Publication Publication Date Title
MX367404B (es) Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides.
CO2019000386A2 (es) Compuestos heterocíclicos como inmunomoduladores
ECSP17074645A (es) Azabenzimidazoles y su uso como moduladores del receptor ampa
CL2018000542A1 (es) Nuevos derivados de fenoximetilo.
MX2019003887A (es) Compuestos, dispositivos y usos de los mismos.
MX2018003432A (es) Compuestos heterociclicos y usos de los mismos.
DOP2016000299A (es) Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y su uso como inhibidores ido1
CL2016003246A1 (es) Compuestos de dihidroisoquinolinona sustituida
MX2017013874A (es) Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa.
GT201600269A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
MX2017009505A (es) Derivados de 9h-pirrolo-dipiridina.
UY36003A (es) Derivados de amida, procesos de preparación y composiciones, útiles en afecciones asociadas con el receptor sub-tipo 1 de orexina.
ECSP17069696A (es) Compuestos novedosos
DOP2018000062A (es) Piridinona dicaboxamidas para uso como inhibidores de bromodominio
CL2017001073A1 (es) 2,4 diamino-quinolia sustituido como nuevos agentes anticancerigenos
SV2016005313A (es) Derivados de carboxamida
CL2019001991A1 (es) Moduladores del receptor de estrógeno.
CL2016002089A1 (es) Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
MX2016011535A (es) Ureas asimetricas p-sustituidas y usos medicos de las mismas.
UY37191A (es) Derivados de dibenzofurano para uso como inhibidores de bromodominio
CO2019004143A2 (es) Compuestos azaheterocíclicos fusionados y su uso como moduladores de los receptores ampa
ECSP16094286A (es) Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas
ECSP18056196A (es) Derivados de indano
AR132461A2 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
CR20190028A (es) Compuestos heterocíclicos como inmunomoduladores

Legal Events

Date Code Title Description
FG Grant or registration